Does New COO Role Change The Bull Case For Boston Scientific (BSX)?
- Boston Scientific reshaped its operating model by appointing Joseph M. Fitzgerald as COO and reorganizing into three reportable segments that group cardiovascular, rhythm management and MedSurg businesses from January 2027, while also managing a Class I recall of Imager II angiographic catheters affecting more than 260,000 devices worldwide.
- The new segment heads, including leaders for Interventional Therapies and Rhythm Solutions, are directly linked to Boston Scientific’s cost saving goals and the planned integration of deals such as Penumbra. This structure could influence how capital is allocated across stronger and weaker procedure areas.
- We will now examine how Boston Scientific’s investment narrative could change as the new COO structure concentrates decision-making power.
Boston Scientific Investment Narrative Recap
To own Boston Scientific, you need to believe the medical device portfolio can keep generating steady procedures while management reshapes the operating model. The new COO role and three segment structure concentrate accountability around Interventional Therapies, Rhythm Solutions and MedSurg at a time when electrophysiology and WATCHMAN are guided to be flat at best, and Penumbra integration still sits ahead.
The key near term swing factor remains execution on restructuring and large deals while holding margin quality. The Class I recall adds operational distraction but does not obviously change the main thesis unless follow on costs or reputational impacts build. Weakness in pulsed field ablation share and WATCHMAN volumes still looks like the biggest business risk.
The most relevant new announcement for this setup is Joseph Fitzgerald’s move to COO alongside the 2027 segment reorganisation. He already oversees Cardiovascular, which includes some of the growth engines that analysts expect to offset softer Rhythm Solutions trends. That continuity may matter as Boston Scientific leans on Interventional Therapies and MedSurg to support earnings quality.
For catalysts, investors are watching whether the reorganised structure actually supports faster decisions on capital allocation into higher margin technologies such as SEISMIQ IVL and future FARAPULSE platform updates. At the same time, the company must absorb the roughly US$14.5b Penumbra deal and the MiRus exposure. Any stumble on the US$500m cost saving target or on integrating Penumbra would push the existing execution risk higher.
What The Current Analyst Framework Implies
Boston Scientific is being valued on a fairly tight set of assumptions that hinge on steady top line expansion and a measured lift in profitability. Analysts are building in 5.4% annual revenue growth over the next three years, a move in profit margins from 17.5% today to 18.1% in three years, and a gradual reduction in share count of about 2.24% per year. That combination frames the integration work around Penumbra and MiRus, the restructuring program, and the new segment structure as levers that need to keep earnings power intact rather than stretch for aggressive outcomes.
On earnings specifically, the consensus view looks for profit to move from US$3.7b today to US$4.4b by 2029, with earnings per share at US$2.98 and analysts described as broadly aligned on that target. The implied step up of roughly US$0.7b in absolute earnings sits alongside the move in margins and assumes that procedural volume, restructuring savings and capital allocation can collectively offset ongoing pressure in electrophysiology and WATCHMAN. For investors tracking Boston Scientific, that earnings bridge effectively becomes a scorecard for whether the COO centred model and the three segment architecture are helping or hindering performance through the recall period and the acquisition cycle.
Valuation thinking around Boston Scientific ties those operating assumptions to a P/E re rating. Analysts reference a forward P/E of 23.3x on 2029 earnings, up from 17.2x today, and point out that this prospective multiple sits below the current 25.1x P/E cited for the broader US medical equipment group. That gap matters for anyone asking whether the stock is already pricing in a clean execution path on the restructuring, recall management and Penumbra integration. A higher future multiple only tends to hold if the earnings path sketched out above feels achievable as quarterly results come through, especially once the new Interventional Therapies, Rhythm Solutions and MedSurg segments start reporting separately.
The current consensus price target of US$61.07, compared with a spot share price of US$43.72, implies that analysts see scope for meaningful upside if the 2029 revenue and earnings framework proves accurate. Targets range from US$44.00 to US$94.00, which signals real dispersion in views on how the recall, cyberattack impact, pulsed field ablation share loss and large deal execution will play out. For readers, that spread can be useful, since it highlights where conviction differs on key swing factors such as the sustainability of interventional cardiology growth and the timing and reliability of the US$500m restructuring savings exiting 2029.
Boston Scientific's narrative projects US$24.5b revenue and US$4.4b earnings by 2029. This is tied to 5.4% yearly revenue growth and an earnings increase of about US$0.7b from US$3.7b today.
Uncover why Boston Scientific's fair value indicates a 43% potential upside to its current price, which could narrow quickly.
Exploring Other Perspectives
One alternate view puts the recall and new Boston Scientific segment structure in a harsher light. The most cautious analysts were pencilling in only 4.2% annual revenue growth and about US$4.1b earnings by 2029 before this news. That is well below consensus and shows how sharply opinions can differ, so explore several angles before deciding what makes sense for you.
Explore 6 other Boston Scientific fair value estimates, including one that suggests it could be worth just $44.00.
Form Your Own Verdict
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider forming your own view.
- A great starting point for your Boston Scientific research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
- See our latest analysis for Boston Scientific. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Boston Scientific's overall financial health at a glance.
Looking For More Investment Ideas Beyond Boston Scientific?
If the Boston Scientific setup has sharpened your thinking about risk, capital allocation and execution, consider broadening that lens to a wider group of companies. A focused screener can help you quickly filter for the traits you care about most instead of scrolling through endless tickers.
- If you want potential value with quality in mind, scan through a curated pool of companies using the 28 high quality undervalued stocks.
- For investors who care about balance sheet strength first, start with a list of solid balance sheet and fundamentals (25 results) and see which businesses meet your risk comfort level.
- When income is the priority, use a targeted list of payout focused stocks by reviewing the 8 dividend fortresses.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com